Status: Recruiting
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
This study is a randomized, open-label, multicenter, prospective clinical trial aimed at evaluating the efficacy and safety of orelabrutinib combined with rituximab for the previously untreat MZL
Participants needed: 90
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Fei LiUpdated: Jun 17, 2025Locations: 1
Eligibility criteria
Patients with central nervous system involvement; [+14]